利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

83 条记录 (耗时 0.038 秒)

    USE OF BIGLYCAN IN THE ASSESSMENT OF HEART FAILURE
    1.
    发明申请
    USE OF BIGLYCAN IN THE ASSESSMENT OF HEART FAILURE 审中-公开
    大智慧在评估心脏失败时的使用

    公开(公告)号：US20110165591A1

    公开(公告)日：2011-07-07

    申请号：US13048196

    申请日：2011-03-15

    申请人： Ursula-Henrike Wienhues-Thelen ,  Sara Arab ,  Dirk Block ,  Andrew Emili ,  Anthony Gramolini ,  Georg Hess ,  Hendrik Huedig ,  Peter Liu ,  David MacLennan

    发明人： Ursula-Henrike Wienhues-Thelen ,  Sara Arab ,  Dirk Block ,  Andrew Emili ,  Anthony Gramolini ,  Georg Hess ,  Hendrik Huedig ,  Peter Liu ,  David MacLennan

    IPC分类号： G01N33/53

    CPC分类号： G01N33/6893 ,  G01N2333/4722 ,  G01N2800/325

    摘要： The invention relates to a method for assessing heart failure in vitro and involves the steps of measuring in a sample the concentration of the marker biglycan, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for biglycan and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of biglycan as a marker protein in the assessment of heart failure, a marker combination comprising biglycan and a kit for measuring biglycan.

    摘要翻译： 本发明涉及一种用于评估体外心脏衰竭的方法，包括以下步骤：在样品中测量标记物双糖链球蛋白的浓度，任选地在样品中测量一种或多种其它心力衰竭标志物的浓度，以及 通过比较确定的双糖甘肽聚糖浓度和任选的一种或多种其他标记物测定的浓度与该参考群体中确定的该标记物或这些标记物的浓度进行比较来评估心力衰竭。 还公开了使用双糖链蛋白作为评估心力衰竭的标记蛋白，包括双糖链蛋白聚糖和用于测量双糖链球蛋白的试剂盒的标记组合。

    USE OF MIMECAN IN THE ASSESSMENT OF HEART FAILURE
    3.
    发明申请
    USE OF MIMECAN IN THE ASSESSMENT OF HEART FAILURE 审中-公开
    MIMECAN在心脏衰竭评估中的应用

    公开(公告)号：US20120156703A1

    公开(公告)日：2012-06-21

    申请号：US13359276

    申请日：2012-01-26

    申请人： Dirk Block ,  Sara Arab ,  Georg Hess ,  Hendrik Huedig ,  Peter Liu ,  Ursula-Henrike Wienhues-Thelen

    发明人： Dirk Block ,  Sara Arab ,  Georg Hess ,  Hendrik Huedig ,  Peter Liu ,  Ursula-Henrike Wienhues-Thelen

    IPC分类号： G01N33/566

    CPC分类号： G01N33/6893 ,  G01N33/6812 ,  G01N2333/4703 ,  G01N2800/325

    摘要： The disclosure relates to assessing heart failure in vitro by measuring the concentration of the marker mimecan in a sample, and optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration of mimecan and the one or more other marker(s) to reference concentrations of this (or these) marker(s) as established in a reference population. The one or more markers may be selected from the group comprising a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation. Also disclosed are the use of mimecan as a marker protein in the assessment of heart failure, a marker combination comprising mimecan, and a kit for measuring mimecan.

    摘要翻译： 本公开涉及通过测量样品中标记拟米卡因的浓度来评估体外心力衰竭，并且可选地在样品中测量一种或多种其他心力衰竭标志物的浓度，并通过比较心脏衰竭来评估心力衰竭 在参考群体中建立的，将拟米卡宁和一种或多种其它标记物浓度提高至（或这些）标记的参考浓度。 一种或多种标志物可以选自利尿钠肽标记物，心肌肌钙蛋白标记物和炎症标志物。 还公开了在评估心力衰竭中使用mimecan作为标记蛋白，包括mimecan的标记组合和用于测量mimecan的试剂盒。

    MYOGLOBIN AS EARLY PREDICTOR OF MYOCARDIAL INFARCTION
    9.
    发明申请
    MYOGLOBIN AS EARLY PREDICTOR OF MYOCARDIAL INFARCTION 失效
    MYOGLOBIN作为心肌梗塞早期预后因素

    公开(公告)号：US20100285595A1

    公开(公告)日：2010-11-11

    申请号：US12720063

    申请日：2010-03-09

    申请人： Georg Hess ,  Hendrik Huedig ,  Rosemarie Kientsch-Engel ,  Dietmar Zdunek

    发明人： Georg Hess ,  Hendrik Huedig ,  Rosemarie Kientsch-Engel ,  Dietmar Zdunek

    IPC分类号： G01N33/72

    CPC分类号： G01N33/6887 ,  G01N2333/805 ,  G01N2800/324

    摘要： The present invention relates to a method for diagnosing myocardial infarction in a subject who suffers from acute coronary syndrome and has a cardiac troponin level, which is detectable, but lower than the level that is considered as being indicative for a myocardial infarction. Moreover, the present invention relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome and has a cardiac troponin level which is detectable, but lower than a level that is considered as being indicative for a myocardial infarction. The methods of the present invention are based on the determination of myoglobin and, optionally, Heart-type fatty acid binding protein (H-FABP) in a sample of said subject and comparing the amount of myoglobin and, optionally, H-FABP to reference amounts. Also comprised by the present invention are kits or devices to carry out the methods of the present invention.

    摘要翻译： 本发明涉及一种用于诊断患有急性冠状动脉综合征且具有心肌肌钙蛋白水平的受试者心肌梗塞的方法，其可检测但低于被认为是指示心肌梗塞的水平。 此外，本发明涉及用于识别易受心脏干预的受试者的方法，其中所述受试者患有急性冠状动脉综合征，并且具有可检测但是低于被认为是指示性的水平的心脏肌钙蛋白水平 心肌梗死 本发明的方法是基于在所述受试者的样品中测定肌红蛋白和任选的心脏型脂肪酸结合蛋白（H-FABP），并将肌红蛋白和任选的H-FABP的量与参考 金额 本发明还包括用于实施本发明方法的试剂盒或装置。

    H-FABP AS EARLY PREDICTOR OF MYOCARDIAL INFARCTION
    10.
    发明申请
    H-FABP AS EARLY PREDICTOR OF MYOCARDIAL INFARCTION 失效
    H-FABP作为心肌梗塞的早期预后因素

    公开(公告)号：US20100159491A1

    公开(公告)日：2010-06-24

    申请号：US12623495

    申请日：2009-11-23

    申请人： Georg Hess ,  Hendrik Huedig ,  Rosemarie Kientsch-Engel ,  Dietmar Zdunek

    发明人： Georg Hess ,  Hendrik Huedig ,  Rosemarie Kientsch-Engel ,  Dietmar Zdunek

    IPC分类号： G01N33/68 ,  G01N33/53

    CPC分类号： G01N33/6893 ,  G01N2800/324

    摘要： The present invention relates to a method for diagnosing myocardial infarction in a subject who suffers from acute coronary syndrome and has a cardiac troponin level which is detectable but lower than the level that is considered as being indicative for a myocardial infarction. Moreover, the present invention relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome and has a cardiac troponin level which is detectable but lower than a level that is considered as being indicative for a myocardial infarction. The methods of the present invention are based on the determination of H-FABP and, optionally, myoglobin in a sample of the subject and comparing the amount of H-FABP and, optionally, myoglobin to reference amounts.

    摘要翻译： 本发明涉及一种用于诊断患有急性冠状动脉综合征并且具有可检测但低于被认为是指示心肌梗死的水平的心肌肌钙蛋白水平的受试者心肌梗塞的方法。 此外，本发明涉及用于识别易受心脏干预的受试者的方法，其中所述受试者患有急性冠状动脉综合征，并且具有可检测但低于被认为是指示心肌的水平的心肌肌钙蛋白水平 梗死。 本发明的方法是基于H-FABP和任选地在受试者样品中的肌红蛋白的测定，并将H-FABP和任选的肌红蛋白的量与参考量进行比较。